0001437749-23-003138.txt : 20230315 0001437749-23-003138.hdr.sgml : 20230315 20230213154956 ACCESSION NUMBER: 0001437749-23-003138 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20230213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Panbela Therapeutics, Inc. CENTRAL INDEX KEY: 0001029125 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870543922 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 712 VISTA BLVD #305 CITY: WACONIA STATE: MN ZIP: 55387 BUSINESS PHONE: 9524791196 MAIL ADDRESS: STREET 1: 712 VISTA BLVD #305 CITY: WACONIA STATE: MN ZIP: 55387 FORMER COMPANY: FORMER CONFORMED NAME: Sun BioPharma, Inc. DATE OF NAME CHANGE: 20150911 FORMER COMPANY: FORMER CONFORMED NAME: Cimarron Medical, Inc. DATE OF NAME CHANGE: 20150602 FORMER COMPANY: FORMER CONFORMED NAME: CIMARRON SOFTWARE INC DATE OF NAME CHANGE: 19961217 CORRESP 1 filename1.htm pbla20230211_corresp.htm

 

February 13, 2023

 

VIA EDGAR TRANSMISSION

 

Division of Corporation Finance

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549-6010

 

Attn: Alan Campbell

 

 

Re:

Panbela Therapeutics, Inc.
   

Registration Statement on Form S-1 (Registration No. 333-269711)
   

Request for Acceleration of Effective Date

 

Ladies and gentlemen:

 

In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), Panbela Therapeutics, Inc. (the “Company”) hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-269711) (the “Registration Statement”) to become effective on February 14, 2023, at 4:30 p.m., Eastern Time, or as soon as thereafter possible. The Company hereby acknowledges its responsibilities under the Act as they relate to the proposes public offering of the securities specified in the Registration Statement.

 

Please direct any questions or comments concerning this request to Joshua L. Colburn of Faegre Drinker Biddle & Reath LLP, counsel to the Company, at +1 (612) 766-8946.

 

[Signature Page Follows]

 

 
 

 

 

Very truly yours,

  
     
 

PANBELA THERAPEUTICS, INC.

 
       
 

By:

/s/ Susan Horvath

  
 

Name: 

Susan Horvath

  
 

Title:

Vice President of Finance, Chief Financial Officer,

Treasurer and Secretary